Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on February 07, 2018, 10:49:39 am
-
About 16 percent of liver cancer patients who used the PD-1 checkpoint inhibitor Keytruda (pembrolizumab) after prior treatment with Nexavar (sorafenib) experienced tumor shrinkage, which in most cases lasted at least six months, according to findings presented at the 2018 Gastrointestinal Cancers Symposium (GI18) last week in San Francisco.
The median progression-free survival—meaning patients were still alive with no worsening of disease—was 4.8 months, representing an improvement over standard therapy for this difficult to treat cancer.
For more...
https://www.hepmag.com/article/keytruda-leads-durable-response-people-advanced-liver-cancer